An FDA advisory committee yesterday voted 13-1 to support the use of Novartis' (NVS +0.85%) tobramycin inhalation powder for patients with cystic fibrosis and whose lungs contain bacteria called Pseudomonas aeruginosa. The antibiotic powder would be more convenient than Novartis older version of tobramycin, which requires a nebulizer machine.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Fri, 9:00AM)
at Zacks.com (Tue, 4:13PM)
at Investor's Business Daily (Mon, 4:49PM)
at Benzinga.com (Mon, 11:34AM)
at Investor's Business Daily (Jan 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs